We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,271

Former FTC Chair Kovacic Rates the Presidential Candidates
  • Baker & Hostetler LLP
  • USA
  • January 27 2016

As has been reported by William McConnell at TheStreet, former FTC Chair Bill Kovacic delivered a frank assessment of the four leading presidential


FTC report tallies Hatch-Waxman settlement in first full year after Actavis
  • Pepper Hamilton LLP
  • USA
  • January 20 2016

On January 13, 2016, the Federal Trade Commission (FTC or the Commission) released an overview of the pharmaceutical patent settlements filed with


TC Heartland: Reigniting the Debate Over Patent Venue Law
  • Baker Botts LLP
  • USA
  • January 8 2016

Twenty-five years ago, the Federal Circuit decided a case that transformed where (and how) patent infringement cases can be litigated. By expanding


The Fitbit and Jawbone litigations take an antitrust turn
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • November 10 2015

Two of the most prominent manufacturers of portable fitness trackersFitbit Inc. and AliphCom (the maker of Jawbone)are engaged in no fewer than six


Split decisions regarding class certification in provigil antitrust lawsuits
  • McDermott Will & Emery
  • USA
  • October 30 2015

In two antitrust class actions in the U.S. District Court for the Eastern District of Pennsylvania, the court denied class certification as to


A no-AG settlement agreement is subject to Actavis’ rule of reason analysis
  • McDermott Will & Emery
  • USA
  • October 30 2015

Plaintiffs, direct purchasers of the brand-name drug Lamictal (lamotrigine), sued Lamictal’s producer, SmithKline Beecham Corporation (SmithKline


Allegations of antitrust and patent misuse surviving a motion to dismiss
  • McDermott Will & Emery
  • USA
  • October 30 2015

The U.S. District Court for the District of New Jersey was tasked with determining whether allegations in Defendants’ antitrust and patent misuse


Accused infringer rides antitrust roller coaster
  • McDermott Will & Emery
  • USA
  • October 30 2015

Addressing antitrust issues in connection with a dismissed patent infringement lawsuit, the U. S. Court of Appeals for the Ninth Circuit affirmed a


Courts determine that non-cash consideration is subject to antitrust scrutiny under Actavis
  • Hausfeld LLP
  • USA
  • October 15 2015

In its landmark decision, FTC v. Actavis, Inc., the Supreme Court resolved a circuit split regarding so-called “reverse payment” or “pay-for-delay”


Application of Standard Essential Patents and FRAND Principles - brief comments on the Provisions on the Prohibition of Abuse of Intellectual Property Rights to Exclude or Restrict Competition
  • Broad & Bright
  • China, USA
  • October 13 2015

The State Administration of Industry and Commerce ("SAIC") officially announced the Provisions on the Prohibition of Abuse of Intellectual Property